Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer.
about
c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant?Allogeneic tumor cell vaccines: the promise and limitations in clinical trialsComparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment methodDifferential expression of cyclin D1 in the human hair follicleTumor heterogeneity: causes and consequencesThe HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.Tracing the tumor lineage.The Clinical Importance of the Heterogeneity of HER2 neu.Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol)Common protein biomarkers assessed by reverse phase protein arrays show considerable intratumoral heterogeneity in breast cancer tissues.Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ hybridization in invasive breast cancer: a single institution studyEncapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system.MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors.HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slideMYC amplification in breast cancer: a chromogenic in situ hybridisation studyIn situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.Rap2A Is Upregulated in Invasive Cells Dissected from Follicular Thyroid Cancer.Tumor Heterogeneity in Breast Cancer.Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.
P2860
Q24803848-3538347F-3FB8-4EE3-9811-18977F15D97BQ26852333-8D0BCD81-B7C1-4BC2-9CAD-DF4675A99025Q28535362-C7768C25-E4B6-4F1B-9AFA-8686B9F1B071Q30978182-2674C149-C130-4941-BD50-69498CFEC017Q33624298-2E51DF6B-B9DA-4370-A515-4589A87C2E10Q33769034-3BB8D43C-1DF2-42A1-A86D-41DC7EF2A91BQ33998432-46C01A89-9DA4-4259-968B-7B646FE41989Q34262620-17974B13-1CF6-467C-81B8-DF9A6074CA7EQ34296534-FFECEB66-362C-4DC6-9C47-5A1370F11CB1Q34301695-33B16556-4797-4005-B8F9-E9D792BBBA78Q34336095-1EF625BA-2E61-436D-A982-E81D4FC5B440Q34478381-B316558C-4C49-4DA6-ACC5-9448733BCD70Q35158754-4609B605-F9FD-45DE-947E-3DD0B975C759Q35723422-4B831141-4480-4D5F-B444-36216A8F2AA5Q35748541-D36CC80F-3CD0-4446-B04F-4D96F81BE872Q35929360-07D3FC3E-FC3F-4781-B810-761659FAC32FQ35984487-7AF646CA-E7A3-44A8-8A81-B840EAEB9682Q36109108-4FDBB1E8-3E05-48B0-A69E-C3C379A4D343Q37045365-DAA52A00-4C2C-40F1-92F9-14B31A1443EFQ37825724-B9F546DD-8CD1-454A-9B32-AA60675077D4Q38407319-65049E29-7500-46BA-AB7D-E6C23332984BQ47146956-03D9D67C-AF6F-40E3-A171-8769830F3C1CQ50101328-B706143E-7AC4-4D30-BF85-1529D3341766
P2860
Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Marked intratumoral heterogene ...... mplification in breast cancer.
@ast
Marked intratumoral heterogene ...... mplification in breast cancer.
@en
type
label
Marked intratumoral heterogene ...... mplification in breast cancer.
@ast
Marked intratumoral heterogene ...... mplification in breast cancer.
@en
prefLabel
Marked intratumoral heterogene ...... mplification in breast cancer.
@ast
Marked intratumoral heterogene ...... mplification in breast cancer.
@en
P2093
P1476
Marked intratumoral heterogene ...... amplification in breast cancer
@en
P2093
Hans Kreipe
Hilke Buurman
Sabine Glöckner
Ulrich Lehmann
Wolfram Kleeberger
P304
P356
10.1097/01.LAB.0000032371.16521.40
P577
2002-10-01T00:00:00Z
P6179
1024911517